A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis

• Status: Not yet recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis. Determine if IV ketorolac provides improved post-procedure analgesia.

Determine if systemic mediators of inflammation are reduced in patients receiving IV ketorolac following ERCP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• All patients presenting to SFGH for ERCP

• Age 18-85

• Do not meet exclusion criteria

Exclusion Criteria:

• Acute pancreatitis at the time of ERCP

• Use of NSAIDs in the previous week

• Peptic ulcer disease

• Severe renal dysfunction

• Pregnancy

• Lithium therapy

• allergy to ketorolac